Royalty Report: Drugs, Cancer, Diagnostic – Collection: 29506

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Diagnostic
  • Pharmaceuticals
  • Therapeutic
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29506

License Grant
Licensor entered into a worldwide Agreement with the Licensee to develop and commercialize Licensor's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with Licensee's proprietary companion diagnostic test, VeriStrat®.
Licensor grants Licensee perpetual, non-exclusive rights to certain intellectual property, including all clinical and biomarker data related to ficlatuzumab, to develop and commercialize VeriStrat and Licensee granted Licensor perpetual, non-exclusive rights to certain intellectual property, including diagnostic data related to VeriStrat, with respect to the development and commercialization of ficlatuzumab; each license includes the right to sublicense.
License Property
VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC).
Field of Use
The VeriStrat test will be a companion diagnostic for ficlatuzumab, The Licensee will make the VeriStrat test available and use commercially reasonable efforts to seek reimbursement in all geographies where ficlatuzumab is approved.

IPSCIO Record ID: 278110

License Grant
The Parties entered this agreement to develop and commercialize ficlatuzumab.  The non-opting out party shall have sole decision-making authority with respect to further development and commercialization of ficlatuzumab.

Licensor granted the perpetual, non-exclusive rights to certain intellectual property, including diagnostic data related to VeriStrat, with respect to the development and commercialization of ficlatuzumab.

License Property
Ficlatuzumab is a hepatocyte growth factor (HGF) inhibitory antibody.  Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (HNSCC) and metastatic pancreatic ductal cancer (PDAC).

VeriStrat® is Licensor’s proprietary companion diagnostic test.  VeriStrat test is a predictive and prognostic blood-based proteomic test for patients with advanced non-small cell lung cancer.

A retrospective exploratory analysis uses VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO’s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA®) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC).

Field of Use
The field of use is the treatment of non-small cell lung cancer in poor prognosis patients.

IPSCIO Record ID: 5622

License Grant
The Licensor hereby grants an exclusive license without the right to grant sublicenses in the Territory to the Licensed Intellectual Property to (a) confirm performance of the Colon 101 ELISA Test and (b) use the Colon 101 ELISA Test to offer and provide services within the cDx Field and the rDx Field.

Licensee and its Affiliates shall have the right to use the Trademarks, solely in connection with the use of the Colon 101 ELISA Test.

CDX field means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

RDX Field means use in vitro diagnostic testing services in Clinical Trials.

The Licensee shall have the right to use the Trademarks.

License Property
The Licensor has developed a blood test known as the Colon 101 ELISA Test  to detect and quantify the Colon 101 protein in serum.
Field of Use
'CDX Field' means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

'RDX Field' means use in in vitro diagnostic testing services in Clinical Trials.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.